Scientists at Synthekine, a cytokine engineering company founded by Professor K. Christopher Garcia, conducted a study implementing his research on ortho-IL-2/IL-2Rβ in non-human primates and murine advanced lymphoma models.66 In the study, subcutaneous repeat dosing of the polyethylene glycol-modified (pegylated) ortho-hIL-2 (denoted as STK-009) in cynomolgus monkeys (Fig. 5A), which possess highly conserved ligand binding residues in IL-2Rβ compared to a human, demonstrated a prolonged in vivo half-life of STK-009 (Fig. 5B and C). The gene discussed is IL2RB; the disease is lymphoma.